Extracellular control of intracellular drug release for enhanced safety of anti-cancer chemotherapy

Sci Rep. 2016 Jun 23:6:28596. doi: 10.1038/srep28596.

Abstract

The difficulty of controlling drug release at an intracellular level remains a key challenge for maximising drug safety and efficacy. We demonstrate herein a new, efficient and convenient approach to extracellularly control the intracellular release of doxorubicin (DOX), by designing a delivery system that harnesses the interactions between the system and a particular set of cellular machinery. By simply adding a small-molecule chemical into the cell medium, we could lower the release rate of DOX in the cytosol, and thereby increase its accumulation in the nuclei while decreasing its presence at mitochondria. Delivery of DOX with this system effectively prevented DOX-induced mitochondria damage that is the main mechanism of its toxicity, while exerting the maximum efficacy of this anti-cancer chemotherapeutic agent. The present study sheds light on the design of drug delivery systems for extracellular control of intracellular drug delivery, with immediate therapeutic implications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Cytosol / drug effects
  • Cytosol / metabolism
  • Doxorubicin / pharmacology
  • Drug Carriers / chemistry
  • Drug Delivery Systems / methods
  • Drug Liberation / drug effects
  • Hep G2 Cells
  • Humans
  • Mice
  • Mice, Inbred ICR
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Doxorubicin